Provided are: a novel transdermally absorbable pharmaceutical composition which has such characteristic properties that the skin permeability of duloxetine or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition can be increased to exhibit an excellent pharmacological effect of duloxetine or the pharmaceutically acceptable salt thereof and the skin irritancy of the pharmaceutical composition is low and a medicine comprising the pharmaceutical composition.The present invention relates to: a novel transdermally absorbable pharmaceutical composition which contains duloxetine or a pharmaceutically acceptable salt thereof as an active ingredient and also contains menthol, isopropyl alcohol and isopropyl myristate and a medicine comprising the pharmaceutical composition. Each of the composition and the medicine according to the present invention contains duloxetine, which has been widely used in clinical practice as a therapeutic agent for depression and is known to be useful as an analgesic agent for chronic pain and the like, as an active ingredient. Therefore, each of the composition and the medicine has excellent efficacy and safety and has extremely high usefulness as a transdermally absorbable anti-depressant agent and a transdermally absorbable analgesic agent which can be used for a long period with good compliance.Linvention concerne : une nouvelle composition pharmaceutique absorbable par voie transdermique qui a des propriétés caractéristiques telles que la perméabilité de la peau à la duloxétine ou un sel pharmaceutiquement acceptable de celle-ci contenu dans la composition pharmaceutique peut être augmentée pour présenter un effet excellent pharmacologique de duloxétine ou du sel pharmaceutiquement acceptable de celle-ci et la propriété irritante de la peau de la composition pharmaceutique est faible et un médicament comprenant la composition pharmaceutique. La présente invention concerne : une nouvelle composition pharmaceu
